Group Mailing 2025-05-01

Priority Lists

Disease Committee	Last Changed
Breast Cancer	3/6/26
Cancer Care Delivery	8/4/25
comboMATCH	10/16/25
Early Therapeutics & Rare Cancers	11/7/25
Gastrointestinal Cancer	12/30/25
Genitourinary Cancer	1/19/26
Head and Neck Cancer	10/16/25
iMATCH	12/3/25
Immunomolecular Therapeutics	12/3/25
Leukemia	12/30/25
Lung Cancer	9/8/25
LungMAP	4/24/25
Lymphoma	10/23/25
Melanoma	11/7/25
Myeloma	10/23/25
myeloMATCH	12/30/25
Other	2/1/14
Palliative Care	10/24/25
Prevention, Screening, and Surveillance	1/1/25
Sarcoma	9/15/07
SWOG CTP	10/16/25
Symptom Management and Survivorship	10/24/25

Scroll Table

Activations

S1800EPhase II-III

Initial Activation - Effective Date 4/28/2025

A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)

Action Codes	FBR
Study Coordinator(s)	Saiama Waqar, M.D., Tianhong Li, M.D., Ph.D
Participants	US INSTITUTIONS ONLY

S2101

Reactivation for Stage II - Effective Date 5/01/2025

Biomarker Stratified CaboZantinib and NivOlumab (BiCaZO) - A phase II study of combining cabozantinib and nivolumab in patients with advanced solid tumors stratified by tumor biomarkers

Action Codes	ER
Study Coordinator(s)	Siwen Hu-Liekskovan, M.D., Ph.D, Paul Swiecicki, M.D,, Katerina Politi, Ph.D.
Participants	ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Closures

Amendments, Revisions, Memoranda

MYELOMATCH

Revision #3 - Version Date 3/21/2025

Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH trials

Action Codes	NR
Study Coordinator(s)	Jerald P. Radich, M.D.

MYELOMATCH

Memorandum - TAP Data Submission Procedures

Master Screening and Reassessment Protocol (MSRP) for the NCI myeloMATCH trials

Action Codes	NR
Study Coordinator(s)	Jerald P. Radich, M.D.

S2000Phase II

Memorandum - Revision #5 Updated Implementation Date

A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases

Action Codes	ER
Study Coordinator(s)	Zeynep Eroglu, MD, M.D., Hussein A Tawbi, MD, M.D.
Participants	ALLIANCE, ECOG-ACRIN, NRG, ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

S2013Phase II

Memorandum - Discontinued Funding for Archival Tissue Submission

Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Action Codes	ER
Study Coordinator(s)	Dawn Hershman, M.D., M.S., Krishna Gunturu, M.D.